Antibiotics

Antibiotics
Mupirocin [HOT]
4-AA [Intermediate] [HOT]

 

 

 

Mupirocin,12650-69-0,USP37
Mupirocin,USP35
Mupirocin,12650-69-0
CAS
12650-69-0
Molecular Formula
C26H44O9
Molecular Weight
500.625
Systematic Name
Mupirocin
Standard
USP37,GMP
Certificate of analysis
Mupirocin,12650-69-0
View via PDF file
Mupirocin,12650-69-0
Specification
Items
Specification
Test result
Appearance
White to Off-white powder
Complies
Identification
Positive
Complies
pH(25℃)
3.5-4.5
3.9
Crystallinity
Meet the requirement
Complies
Water
Not more than 1.0%
0.1%
Residual solvents
Ethyl acetate:Not more than 500ppm
Complies
Isobutyl acetate:Not more than 5000ppm
Heptane:Not more than 500ppm
Acetone:Not more than 500ppm
Assay(Dried basis)
92.0%-102.0%
95.0%
Contact us for more information
Chemical information
Compound Name*
CAS No. "N/A" if the CAS not available*
Quantity*
Contact information
Contact person*
Email Address *
Tel No.*
Company or Organization Name*
Shipping Address*
Country
Remarks

<Privacy policy: the contact information will be only used for this business contact>

University Client of Mupirocin,12650-69-0

J. K. Sohng in Institute of Biomolecule Reconstruction, Department ofPharmaceutical Engineering, Sun Moon University,South Korea has purchased Mupirocin,12650-69-0 from us in 2011 and a paper named <<Enzymatic glycosylation of the topical antibiotic mupirocin>> has been published in 2014.Please kindly find following link to learn more information:

http://www.researchgate.net/publication/264315262_Enzymatic_glycosylation_of_the_topical_antibiotic_mupirocin

Packing
Ketanserin,74050-98-9
Packing 1
1g
Packing 2
10g
Packing 3
100g
Packing 4
1000g
Packing 5
5000g
Bulk request
sales@lanospharma.com
Related Antibiotics
Mupirocin [HOT]
4-AA [Intermediate]
 
Patent Disclaimer
PD1
Products protected by valid patents are not offered for sale in jurisdictions where the sale of such products constitutes a patent infringement. The current list only reflects the products and technologies that are available, under development: note that some products may be developed or produced for internal and experimental uses with no commercal aim.
PD2
Sales of products are limited to those allowed by Chapter VII PLPRC 63, the above includes Research and development quantities.
PD3
the buyer assumes responsibility of all patent considerations in the use of
Lano ’s Pharmaceutical Co.,Ltd product(Mupirocin,12650-69-0).
PD4
R&D use in accordance with (1) 35 USC 271(e)+A13(1) in the U.S.; (2) Section 69.1 of Japanese Patent Law in Japan; (3) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (4) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (5) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (6) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (7) such similar laws and rules as may apply in various other countries.